Perspective - Journal of Diabetes Medication & Care (2025) Volume 8, Issue 5
Ethnic Variability in Drug Response: Implications for Personalized Diabetes Therapy
Dr. Samuel Okoye*
Dept. of Endocrine Medicine, Lagos Biomedical University, Nigeria
- *Corresponding Author:
- Dr. Samuel Okoye
Dept. of Endocrine Medicine, Lagos Biomedical University, Nigeria
E-mail: samuel.okoye@lbu.ng
Received: 01-Oct-2025, Manuscript No. jdmc-26-184901; Editor assigned: 04- Oct -2025, PreQC No. jdmc-26-184901 (PQ); Reviewed: 18- Oct -2025, QC No. jdmc-26-184901; Revised: 21- Oct -2025, Manuscript No. jdmc-26-184901 (R); Published: 31- Oct -2025, DOI: 10.37532/JDMC.2025.7(5). 300
Introduction
Individual response to diabetes medications is influenced by a combination of genetic, environmental, and cultural factors. Ethnic variability plays a significant role in determining drug efficacy, pharmacokinetics, and susceptibility to adverse effects. Understanding these differences is essential for tailoring therapy, optimizing glycemic control, and reducing complications in diverse populations. Personalized diabetes management must account for ethnic-specific responses to ensure safety and therapeutic effectiveness [1,2].
Discussion
Genetic polymorphisms affecting drug metabolism, transport, and receptor sensitivity contribute to ethnic variability in pharmacologic response. For example, variations in genes encoding cytochrome P450 enzymes can alter the metabolism of sulfonylureas, DPP-4 inhibitors, and other oral hypoglycemics. Patients from East Asian populations often demonstrate increased sensitivity to sulfonylureas, resulting in greater glucose-lowering effects but higher hypoglycemia risk compared with Caucasian populations. Conversely, some African and Hispanic populations may have reduced response to certain insulin secretagogues, necessitating alternative strategies [3,4].
Ethnic differences also influence the pharmacodynamics of newer therapies. SGLT2 inhibitors, which promote renal glucose excretion, may have variable efficacy based on differences in renal function prevalence, body composition, and baseline glycosuria among populations. GLP-1 receptor agonists demonstrate variable weight loss and glycemic outcomes in different ethnic groups, potentially reflecting genetic, metabolic, or lifestyle factors. Statistics highlight these disparities: for instance, studies have shown that while GLP-1 receptor agonists are effective across groups, Black and Hispanic patients are often 20% to 30% less likely to be prescribed these newer, cardio-protective agents compared to White patients, regardless of insurance status.
Beyond genetics, environmental and cultural factors modulate drug response. Dietary habits, physical activity, and adherence patterns differ across populations and can influence both efficacy and side-effect profiles. Socioeconomic factors, healthcare access, and cultural perceptions of treatment also affect real-world outcomes, highlighting the need for population-specific education and counseling [5].
Incorporating ethnic variability into clinical decision-making supports precision medicine. Dose adjustments, careful monitoring, and selective drug choice based on population-specific evidence can minimize adverse effects and enhance efficacy. Clinical trials increasingly include diverse populations to capture these differences and inform guideline recommendations.
Conclusion
Ethnic variability in drug response is a critical consideration in diabetes management. Genetic, metabolic, and cultural factors can significantly influence efficacy, safety, and adherence, emphasizing the need for personalized therapy. Recognizing these differences allows clinicians to optimize drug selection, dosing, and monitoring for diverse populations, improving outcomes and reducing complications. As precision medicine advances, integrating ethnic-specific data into diabetes care will become increasingly essential for equitable and effective treatment.
References
- Jomezadeh N, Babamoradi S, Kalantar E, Javaherizadeh H (2014) Isolation and antibiotic susceptibility of Shigella species from stool samplesamong hospitalized children in Abadan, Iran. Gastroenterol Hepatol Bed Bench 7: 218.
- Sangeetha A, Parija SC, Mandal J, Krishnamurthy S (2014) Clinical and microbiological profiles of shigellosis in children. J Health Popul Nutr 32: 580.
- Ranjbar R, Dallal MMS, Talebi M, Pourshafie MR (2008) Increased isolation and characterization of Shigella sonnei obtained from hospitalized children in Tehran, Iran. J Health Popul Nutr 26: 426.
- Zhang J, Jin H, Hu J, Yuan Z, Shi W, et al. (2014) Antimicrobial resistance of Shigella spp. from humans in Shanghai, China, 2004â2011. Diagn Microbiol Infect Dis 78: 282â286.
- Pourakbari B, Mamishi S, Mashoori N, Mahboobi N, Ashtiani MH, et al. (2010) Frequency and antimicrobial susceptibility of Shigella species isolated in children medical center hospital, Tehran, Iran, 2001â2006. Braz J Infect Dis 14: 153â157.
